Related Experiment Video

Updated: Feb 14, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.9K

High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma

Philip Eliades1, Brian J Abraham2, Zhenyu Ji3

  • 1Wellman Center for Photomedicine and Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Dermatology, Weill Cornell Medical College, New York, New York, USA; Signature Healthcare Brockton Hospital, Brockton, Massachusetts, USA.

The Journal of Investigative Dermatology
|February 7, 2018
PubMed

Insights

Super-enhancers significantly drive MITF overexpression in melanoma. CDK7 inhibition effectively targets these super-enhancers, offering a potential new therapeutic strategy for melanoma by suppressing tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Cutaneous melanoma is an aggressive skin cancer responsible for most skin cancer deaths.
  • Lineage dependency, driven by genes like MITF, promotes melanoma cell survival and therapeutic resistance.
  • MITF overexpression is a key factor in melanoma progression, often linked to gene amplification.

Purpose of the Study:

  • To investigate the role of super-enhancers in MITF overexpression in melanoma.
  • To evaluate the efficacy of CDK7 inhibition as a therapeutic strategy for melanoma.
  • To explore the impact of CDK7 inhibition on MITF and SOX10 expression and melanoma cell growth.

Main Methods:

  • Analysis of super-enhancer involvement in MITF overexpression in melanoma cell lines and tumors.
  • In vitro and in vivo assessment of melanoma cell sensitivity to the CDK7 inhibitor THZ1.
  • Evaluation of THZ1's effect on super-enhancers of MITF and SOX10, and subsequent gene expression levels.

Main Results:

  • Super-enhancers are identified as significant drivers of MITF overexpression in a subset of melanoma.
  • Melanoma cells exhibit high sensitivity to CDK7 inhibition, both in vitro and in vivo.
  • THZ1 treatment effectively dismantles super-enhancers at MITF and SOX10, leading to reduced intracellular levels of these proteins.

Conclusions:

  • CDK7 inhibition represents a promising therapeutic avenue for melanoma by targeting critical oncogenic transcription factors.
  • Disrupting super-enhancers associated with MITF and SOX10 via CDK7 inhibition can suppress melanoma tumor growth.
  • This study reveals a novel regulatory mechanism for MITF in melanoma and highlights CDK7 as a potential therapeutic target.

More Related Videos

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.2K
Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

14.2K

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.4K
What is Gene Expression?01:42

What is Gene Expression?

Overview
Gene expression is the process in which DNA directs the synthesis of functional products, that is, proteins. Cells can regulate gene expression at various stages. It allows organisms to generate different cell types and enables cells to adapt to internal and external factors.
Genetic Information Flows from DNA to RNA to Protein
A gene is a stretch of DNA that serves as the blueprint for functional RNAs and proteins. Since DNA is made up of nucleotides and proteins consist of amino...
197.2K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.9K
Super-resolution Fluorescence Microscopy01:37

Super-resolution Fluorescence Microscopy

Super-resolution fluorescence microscopy (SRFM) provides a better resolution than conventional fluorescence microscopy by reducing the point spread function (PSF). PSF is the light intensity distribution from a point that causes it to appear blurred. Due to PSF, each fluorescing point appears bigger than its actual size, and it is the PSF interference of nearby fluorophores that causes the blurred image. Various approaches to achieving higher resolution through SRFM have recently been...
14.6K
Self-Evaluation: Self-Enhancement and Self-Verification03:00

Self-Evaluation: Self-Enhancement and Self-Verification

Social psychologists have documented that feeling good about ourselves and maintaining positive self-esteem is a powerful motivator of human behavior (Tavris & Aronson, 2008). In the United States, members of the predominant culture typically think very highly of themselves and view themselves as good people who are above average on many desirable traits (Ehrlinger, Gilovich, & Ross, 2005). Often, our behavior, attitudes, and beliefs are affected when we experience a threat to our...
5.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K